Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 12/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8761736 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8754825 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8748862 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8749186 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8761610 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8748934 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL242586 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8748944 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL9151061 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL3425106 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-10577319-B2 | Process for preparing alkyl pyroglutamic acids | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180201578-A1 | PROCESS FOR PREPARING ALKYL PYROGLUTAMIC ACIDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201578-A1 | PROCESS FOR PREPARING ALKYL PYROGLUTAMIC ACIDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-07-19 | — | — | US | disclosed |
| EP-2763964-B1 | PROCESS FOR PREPARING ALKYL PYROGLUTAMIC ACIDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20160237033-A1 | PROCESS FOR PREPARING ALKYL PYROGLUTAMIC ACIDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237033-A1 | PROCESS FOR PREPARING ALKYL PYROGLUTAMIC ACIDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9260388-B2 | Process for preparing alkyl pyroglutamic acids | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260388-B2 | Process for preparing alkyl pyroglutamic acids | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140342966-A1 | PROCESS FOR PREPARING ALKYL PYROGLUTAMIC ACIDS | DOW GLOBAL TECHNOLOGIES LLC | 2014-11-20 | — | — | US | disclosed |
| US-5472946-A | Topical administration of lincomycin, clindamycin, erthromycin and iododeoxyuridine on skin or mucuous membranes | DISCOVERY THERAPEUTICS, INC. | 1995-12-05 | — | — | US | disclosed |
| US-5470848-A | Penetration enhancers for transdermal delivery of systemic agents | DISCOVERY THERAPEUTICS, INC. | 1995-11-28 | — | — | US | disclosed |
| US-5444075-A | Penetration enhancers for transdermal delivery of systemic agents | MINASKANIAN GEVORK (US) | 1995-08-22 | — | — | US | disclosed |
| US-5411978-A | Aging resistance, human skin | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1995-05-02 | — | — | US | disclosed |
| US-5338747-A | Benzoisothiazolinone-1-dioxide derivatives as elastase inhibitors | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1994-08-16 | — | — | US | disclosed |
| US-5234959-A | Omega-dialkylaminoalkanoic acids; drug delivery directly to the bloodstream | WHITBY RESEARCH, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5118692-A | Penetration enhances for transdermal delivery of systemic agents | WHITBY RESEARCH, INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-5118676-A | Administering carboxylic derivatives as enhancer with systemically active agents | WHITBY RESEARCH, INC. (US) | 1992-06-02 | — | — | US | disclosed |
| EP-0446047-A1 | Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors | UNILEVER PLC (GB) | 1991-09-11 | — | — | EP | disclosed |
| US-4996199-A | Penetration enhancers for transdermal delivery of systemic agents | WHITBY RESEARCH, INC. (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577319-B2 | Process for preparing alkyl pyroglutamic acids | GRHPR, GLO1, GCG | MEN1 1122/4885KMT2A 2249/4885POLB 218/4885 |
| US-20160237033-A1 | PROCESS FOR PREPARING ALKYL PYROGLUTAMIC ACIDS | GRHPR, GLO1, GCG | MEN1 1122/4885KMT2A 2249/4885POLB 218/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | MEN1 4840/4885KMT2A 2718/4885POLB 2615/4885 |
| US-20180201578-A1 | PROCESS FOR PREPARING ALKYL PYROGLUTAMIC ACIDS | GRHPR, GLO1, GCG | MEN1 1122/4885KMT2A 2249/4885POLB 218/4885 |
| US-20140342966-A1 | PROCESS FOR PREPARING ALKYL PYROGLUTAMIC ACIDS | GLO1, PLOD1, GRHPR | MEN1 1094/4885KMT2A 2713/4885POLB 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.